close
References
  1. Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020;21(8):2956.
  2. Robert C, Peris K, Migden M. Unlocking the potential of immuno-oncology in advanced cutaneous squamous cell carcinoma: role of checkpoint blockade. EMJ Dermatol. 2019;7(suppl 1):2-10.
  3. Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017;31(suppl 2):5-7.
  4. Riihilä P, Nissinen L, Knuutila J, Rahmati Nezhad P, Viiklepp K, Kähäri VM. Complement system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(14):3550.
  5. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012;122(2):464-472.
  6. Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S. Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:1-10.
  7. Nissinen L, Farshchian M, Riihilä P, Kähäri VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res. 2016;365(3):691-702.
  8. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501.
  9. Ogata D, Tsuchida T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma. Curr Treat Options Oncol. 2019;20(4):30.
  10. Fitzgerald K, Tsai KK. Systemic therapy for advanced cutaneous squamous cell carcinoma. Semin Cutan Med Surg. 2019;38(1):E67-E74.
  11. Stenman C, Gonzalez H, Gillstedt M, et al. Degree of differentiation of cutaneous squamous cell carcinoma: a comparison between a Swedish cohort of organ transplant recipients and immunocompetent patients. Dermatol Pract Concept. 2018;8(4):330-336.
  12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 2.2020. July 14, 2020. www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed July 25, 2020.
  13. van Lee CB, Roorda BM, Wakkee M, et al. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. Br J Dermatol. 2019;181(2):338-343.
  14. Potenza C, Bernardini N, Balduzzi V, et al. A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma. Biomed Res Int. 2018;2018:9489163.
  15. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419-3426.
  16. Foote MC, McGrath M, Guminski A, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047-2052.
  17. Samstein RM, Ho AL, Lee NY, Barker CA. Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer. 2014;2014:284582.
  18. Farberg AS, Goldenberg G. New guidelines of care for the management of nonmelanoma skin cancer. Cutis. 2018;101(5):319-321.
  19. Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019;5(9):763-766.
  20. Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology clinical practice guideline. Pract Radiat Oncol. 2020;10(1):8-20.
  21. Porceddu SV, Bressel M, Poulsen MG, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018;36(13):1275-1283.
  22. Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019;12(10):947-951.
  23. Cemiplimab-rwlc. Package insert. Regeneron Pharmaceuticals, Inc.; 2020.
  24. Food and Drug Administration. FDA approves pembrolizumab for cutaneous squamous cell carcinoma. www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma. June 24, 2020. Accessed November 23, 2020.
  25. Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351.
  26. Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1):e000775.
  27. Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294-305.
  28. Regeneron. FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma. September 28, 2018.
  29. Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916-2925.
  30. Maubec E, Boubaya M, Petrow P, et al; Groupe de Cancérologie Cutanée30. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol. 2020;38(26):3051-3061.
  31. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Cutaneous+Squamous+Cell+Carcinoma&flds=aby&recrs=b&recrs=a&age_v
    =&gndr=&type=Intr&rslt=&Search=Apply    . Accessed July 12, 2020.
  32. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249-261.
  33. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76-83.
  34. Virgen CA, Nguyen TA, Di Raimondo C, et al. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2020;6(3):195-197.
  35. Sun CW, Grossman SK, Aphale A, Hsu S. Pembrolizumab-induced bullous pemphigoid. JAAD Case Rep. 2019;5(4):362-364.
  36. Pembrolizumab. Package insert. Merck & Co., Inc.; 2020.
  37. Migden MR, Schlesinger TE, Schmults CD, et al. Multidisciplinary expert-driven consensus on the evolving treatment of patients with advanced cutaneous squamous cell carcinoma. SKIN The Journal of Cutaneous Medicine. 2019;3:S50.
  38. Work Group; Invited Reviewers, Kim JYS, Kozlow JH, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578.
  39. Association of Community Cancer Centers. Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma Care: Models of Effective Care Delivery. 2019. www.accc-cancer.org/projects/advanced-squamous-cell-carcinoma/overview. Accessed November 24, 2020.